Genetic Signatures

Genetic Signatures Market capitalization

The The market capitalization of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 26.12 M AUD. In the previous year, The market capitalization was 26.12 M AUD — a change of 0.00% (lower).

Market capitalization

26.12 MAUD

YoY

0.00%

Last updated:

In 2026, Genetic Signatures's market cap stood at 26.12 M AUD, a 0.00% increase from the 26.12 M AUD market cap in the previous year.

The Genetic Signatures Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2019
26.12 M AUD
Jan 1, 2020
26.12 M AUD
Jan 1, 2021
26.12 M AUD
Jan 1, 2022
26.12 M AUD
Jan 1, 2023
26.12 M AUD
Jan 1, 2024
26.12 M AUD
Jan 1, 2025
26.12 M AUD
Jan 1, 2026
26.12 M AUD
The Genetic Signatures Market capitalization history
YEARMarket capitalizationYoY
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD0.00%
26.12 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Genetic Signatures's Market Capitalization

Genetic Signatures's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Genetic Signatures's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Genetic Signatures's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Genetic Signatures’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Genetic Signatures stock

The market capitalization of Genetic Signatures is 26.12 M AUD in 2026.

The market capitalization of Genetic Signatures changed from 26.12 M AUD to 26.12 M AUD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's AUD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' AUD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Genetic Signatures

All Key Metrics — Genetic Signatures